From: Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study
Reference | No. of ALS Patients (pts) | Primary end point | Methods | Conclusions |
---|---|---|---|---|
Kimura et al. (2006) [8] | 82 sALS (15 possible, 32 probable, and 35 definite) | Death or tracheostomy or non-invasive ventilation | Mean ΔFS based on ALSFRS-R score on time of diagnosis. Two groups: ΔFS < 0.67 vs ΔFS ≥ 0.67 Three groups (arbitrary cut-off): ΔFS < 0.5 vs 0.5 ≤ ΔFS < 1 vs ΔFS ≥ 1 | Risk of death increased progressively from lowest to highest ΔFS. ΔFS is a good independent predictor of survival time. |
Gordon et al. (2006) [13] | 112 ALS patients (not further specified) | 6-month change in ALSFRS-R. | ΔFS based on ALSFRS-R score on time of diagnosis Two groups: ΔFS < 0.5 vs ΔFS ≥ 0.5 | ΔFS is an excellent predictor of the progression rate at time of diagnosis and for stratification in clinical trials. |
Elamin et al. (2015) [9] | 204 Irish patients 122 Italian patients (possible, probable or definite ALS) | Survival time from initial visit (until death or census date at least 50 months after initial visit) | ΔFS based on ALSFRS-R score on time of inclusion into study Four groups: ΔFS < 0.25 vs 0.25 ≤ ΔFS < 0.49 vs 0.50 ≤ ΔFS < 0.99 vs ΔFS ≥ 1.00 | ΔFS for Irish cohort good as independent predictor but a poor predictor for Italian cohort |
Labra et al. (2016) [12] | 164 patients (suspected, probable, possible or definite) | Survival from initial visit (until death) | Three groups: ΔFS < 0.47 vs 0.47 ≤ ΔFS < 1.11 vs ΔFS ≥ 1.11 | ΔFS is a simple, robust independent prognostic biomarker usable for clinical trials. |